Secretory-and lipoprotein-associated phospholipases A2 (sPLA2 and Lp-PLA2) are enzymes both suggested to be of importance for atherosclerosis. We investigated relationships between the activities of these enzymes in the circulation and atherosclerosis as well as future clinical events.
Introduction
Secretory-and lipoprotein-associated phospholipases A2 (sPLA2 and Lp-PLA2) are two classes of phospholipases implicated in the pathogenesis of atherosclerosis. They both catalyse the hydrolysis of lipoproteins leading to the generation of potent lipid mediators. Secretory-associated phospholipase A2 isoforms (sPLA2-IIA, III, V, and X) play an additional major role in low density lipoprotein (LDL)-C modifications, making LDL-C more susceptible to retention in the subintimal space, increasing their uptake by macrophages and promoting foam cell formation (reviewed in Mallat et al. 1 and Karabina et al. 2 ).
Both of these classes of phospholipases have been found in increased amounts in advanced atherosclerotic plaques and were associated with signs of plaque inflammation and vulnerability. 3 -7 Lack or knock-out of sPLA2 genes on an atherogenic background reduced and the overexpression of the genes increased the amount of atherosclerosis. 8 -12 Furthermore, the pharmacological inhibition of either sPLA2 or Lp-PLA2 activity has been shown to reduce the atherosclerotic lesion size or complexity in experimental models of the disease, 13, 14 giving further proof of an important role of phospholipases in atherosclerosis.
However, Lp-PLA2 and the sPLA2 enzymes are molecularly and biochemically distinct. They bind to and hydrolyse lipoproteins in distinct and specific manners, suggesting unique and different roles in vascular inflammation and atherosclerosis (reviewed in Mallat et al. 1 ).
Since measurements of the activities of sPLA2 and Lp-PLA2 have become available, high Lp-PLA2 activity has been linked to atherosclerosis in humans in both the coronary and carotid arteries (reviewed in Mallat et al. 1 ). Furthermore, both of these markers have been shown to be predictive of future cardiovascular (CV) events in patient groups or in population samples (reviewed in Mallat et al. 1 ).
However, no study has yet evaluated, in the same setting, the association between these two phospholipases and atherosclerosis, or their power to predict mortality in patients with or without CV disease. We therefore assessed these relationships by using data from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study 15 and the French registry of Acute STelevation and non-ST-elevation Myocardial Infarction (FAST-MI). 16 Methods Please refer to Supplementary material online for all information regarding patient population, blood measurements, evaluation of atherosclerosis by ultrasound and magnetic resonance imaging, description of end-points, and statistical analyses.
Results
The PIVUS sample Secretory-and lipoprotein-associated phospholipase A2 activities In the total sample, the median values for sPLA2 and Lp-PLA2 activities were 53.7 U/mL [inter-quartile range (IQR) 44.1-66.5] and 31.5 nmol/mL/min (IQR 22.2-43.8), respectively. For sPLA2, the activity was 19% higher in females than in males (P ¼ 0.0001 for gender difference), whereas for Lp-PLA2, the activity was 9% higher in males than in females (P ¼ 0.013 for gender difference).
Relation of secretory-and lipoprotein-associated phospholipase A2 activities to risk factors
Following adjustment for gender and analysing each risk factor separately, sPLA2 activity was significantly related to waist circumference, serum triglycerides, body mass index (BMI), C-reactive protein (CRP), and inversely related to GFR (see Table 1 for details). Lipoprotein-associated phospholipase A2 activity was significantly related to waist circumference, serum triglycerides, LDL-C, and inversely related to alcohol intake and educational level in linear regression models.
In multiple fractional polynomial regression with all risk factors in the models and with P , 0.05 as significance level, only gender, CRP, and GFR (inversely) were significantly related to sPLA2 activity, and only waist circumference and LDL-C were significantly related to Lp-PLA2 activity. The multiple fractional polynomial regression model did not disclose any significant non-linear relationships.
Relation of secretory-and lipoprotein-associated phospholipase A2 activities to a carotid artery plaque Secretory-associated phospholipase A2 [odds ratio (OR) 1.16 for 1 SD increase, 95% confidence interval (CI): 1.02-1.31, P ¼ 0.018], but not Lp-PLA2 (OR 1.07, 95% CI: 0.95-1.20, P ¼ 0.262), activity was significantly related to carotid atherosclerosis following gender adjustment only. No significant interaction between gender and sPLA2 activity regarding the carotid artery plaque was seen. The following analyses were therefore adjusted, not stratified, for gender.
The inclusion of a quadratic term for sPLA2 activity in the model did not disclose any significant non-linear relationship vs. carotid atherosclerosis. The relationship between sPLA2 activity and carotid atherosclerosis remained significant following adjustment for multiple risk factors, antihypertensive medication and statin use (OR 1.23, 95% CI: 1.05-1.44, P ¼ 0.007; see Table 2 for details).
Relation of secretory-and lipoprotein-associated phospholipase A2 activities to the total atherosclerotic score at magnetic resonance angiography sPLA2 (regression coefficient 0.091 for 1 SD increase, 95% CI: 0.031 -0.14, P ¼ 0.003), but not Lp-PLA2 (regression coefficient 20.0091, 95% CI: 20.058 to 0.040, P ¼ 0.72), activity was significantly related to atherosclerosis following gender adjustment only.
No significant interaction between gender and sPLA2 activity regarding the total atherosclerotic score was seen. The following analyses were therefore adjusted, not stratified, for gender.
The inclusion of a quadratic term for sPLA2 activity in the model did not disclose any significant non-linear relationship vs. atherosclerosis. The relationship between sPLA2 activity and the total atherosclerotic score at magnetic resonance (MR) angiography actually was still significant following adjustment for multiple risk factors, antihypertensive medication and statin use (regression coefficient 0.081, 95% CI: 0.023-0.14, P ¼ 0.006, see Table 2 for details). Due to skewness, the following variables were ln-transformed before analysis: sPLA2 activity, glucose, triglycerides, CRP, GFR, and alcohol intake. Data for sPLA2 are given on an SD scale. OR, odds ratio; CI, confidence interval; BMI, body mass index; CRP, C-reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein.
Relation of secretory-and lipoprotein-associated phospholipase A2 activities to all-cause mortality The median follow-up time was 7.0 years (range 0.3 -8.9 years). During 6973 patient-years at risk, 114 individuals have died. When adjusted for gender only, sPLA2 [hazard ratio (HR) 1.36 for 1 SD increase, 95% CI: 1.14 -1.63, P ¼ 0.001], but not Lp-PLA2 (HR 0.94, 95% CI: 0.78-1.13, P ¼ 0.55), activity was a significant predictor of all-cause mortality.
No significant interaction between gender and sPLA2 activity regarding all-cause mortality was seen. The following analyses were therefore adjusted, not stratified, for gender.
The inclusion of a quadratic term for sPLA2 activity in the model did not disclose any significant non-linear relationship vs. all-cause mortality. Including the variable 'prevalent CV disease' (MI, angina pectoris, stroke, and heart failure) did only marginally change the HR for sPLA2 activity (HR 1.32 for 1 SD increase, 95% CI: 1.11 -1.56, P ¼ 0.002 following adjustment for prevalent CV disease). Secretory-associated phospholipase A2 activity remained an independent predictor of all-cause mortality following adjustment for multiple risk factors, antihypertensive medication and statin use (HR 1.45, 95% CI: 1.15-1.84, P ¼ 0.001, see Table 3 for details). The addition of sPLA2 activity to this set of multiple risk factors was highly significant when calculated by the likelihood ratio test (P ¼ 0.0024). Using a backward stepwise procedure with the same independent variables as in Table 3 , the following four variables remained significant in the model: sPLA2 activity (HR 1.37, 95% CI: 1.14 -1.64), female gender (HR 0.53, 95% CI: 0.35 -0.80), smoking (HR 1.91, 95% CI: 1.17-3.10), and exercise habits (HR 0.69, 95% CI: 0.51-0.90).
Further adding a variable on the carotid artery plaque to this multiple model reduced HR for sPLA2 activity to some degree, although it was still significant (HR 1.35 for 1 SD increase, 95% CI: 1.06-1.71, P ¼ 0.016, following adjustment also for the carotid plaque).
If we exclude the 72 subjects with prevalent myocardial infarction, the 37 subjects with prevalent stroke and the 38 subjects reporting a history of heart failure (some overlap exists), the gender-adjusted HR of 1.36 for a 1 SD change (95% CI: 1.14-1.63, P ¼ 0.001) seen in the total sample actually slightly increase (HR 1.43, 95% CI: 1.14-1.78, P ¼ 0.001).
When sPLA2 activity was divided in quartiles, a significant predictive power for all-cause mortality was seen only for the fourth quartile when compared with the first (reference) quartile when adjusted for gender only ( Table 4 and Figure 1 ). This was the case also following adjustment for multiple risk factors, antihypertensive medication and statin use.
According to the Hosmer-Lemshow test, the calibration for sPLA2 activity was good (P ¼ 0.36). In a multiple stepwise Cox Multiple adjustment was for the following risk factors (gender, waist circumference, serum triglycerides, BMI, CRP, HDL-C, LDL-C, triglycerides, GFR, fasting glucose, blood pressure, antihypertensive medication, alcohol intake, education level, smoking, statin use, and exercise habits). Data for sPLA2 activity as a continuous variable are ln-transformed and are given on an SD scale. HR, hazard ratio.
proportional hazard model with the forward selection of variables with a P-value of ,0.20, only gender, antihypertensive treatment, BMI, and exercise habits remained in the model when all risk factors included in Table 1 plus antihypertensive treatment and statin use were used as independent variables. These four variables showed a receiver operating characteristic area under the curve (ROC-AUC) of 0.6284. Adding sPLA2 activity to that model increased the C-statistics to 0.6459 (P ¼ 0.36). Another analysis of discrimination using integrated discrimination improvement (IDI) showed an improvement by 0.0192 [standard error (SE) 0.00646, P , 0.0029]. Lp-PLA2 activity was not significantly related to future all-cause mortality when treated as a continuous variable (HR 0.94, 95% CI: 0.78 -1.13, P ¼ 0.55). Neither did a quartile analysis revealed any significant association (HR 1.02, 95% CI: 0.59-1.77, P ¼ 0.94, for highest vs. lowest quartile).
Despite the large difference in HRs between sPLA2 and Lp-PLA2 activities regarding future mortality, no significant differences were found between sPLA2 and Lp-PLA2 in bootstrap analysis (P ¼ 0.07).
The FAST-MI sample
Baseline demographics and clinical presentation As shown in Table 5 , the baseline characteristics of patients varied according to sPLA2 activity. Patients in the highest tertile of sPLA2 activity were more likely older, with the higher frequency of previous hypertension, diabetes, CAD, and chronic renal failure. They less frequently received reperfusion therapy, b-blockers, and calcium channel blockers, but received more often angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers and diuretics ( Table 5) . Patients who had an outcome event (death or non-fatal MI) during 1-year follow-up were older (75 + 12 vs. 65 + 13 years) than those without an outcome event and a smaller proportion were male (60 vs. 72%; Table 6 ). They also had a higher rate of hypertension (80 vs. 60%), diabetes (50 vs. 29%), prior myocardial infarction (25 vs. 16%), and heart failure or renal failure (15 vs. 4%). In addition, they were less likely to be treated during the first 48 h following admission with reperfusion therapy, statins (67 vs. 81%), b-blockers (49 vs. 75%), clopidogrel (79 vs. 90%), or heparin (76 vs. 84%) but more often received diuretics (63 vs. 30%), and digitalis treatment (5 vs. 2%) compared with those without outcome event during the follow-up ( Table 6 ).
Relation of secretory-and lipoprotein-associated phospholipase A2 activities to clinical outcome
Of the 1029 patients enrolled, 136 patients (13.2%) died or had a myocardial infarction during the 1-year follow-up period.
The probability of outcome events (death or MI) as a function of baseline sPLA2 activity is presented in Figure 2 . At 1 year, the event rate for death and MI increased across tertiles of sPLA2 activity [25 (8%), 38 (11%), and 73 (20%) in tertile one through tertile 3, respectively]. The respective hazard ratios for the event rate in the second and third tertiles of sPLA2 activity were 1.54 (95% CI: 0.93-2.55) and 2.72 (1.73-4.29), compared with the lowest tertile (P for trend , 0.0001).
After adjustment for known CV risk factors, CRP, Lp-PLA2 activity, and treatments including statins, sPLA2 activity remained an independent correlate of the risk of death or MI. The hazard risks of death or recurrent MI with increasing tertiles of sPLA2 activity were 1.62 (0.96-2.72) and 1.92 (1.17-3.17) compared with the first tertile (P for trend ¼ 0.037). Covariables that contributed to the decrease in HR for sPLA2 activity from 2.72 to 1.92 after multivariate adjustment were essentially age, diuretic treatments, and Killip class. The corresponding hazard risks of death or recurrent MI with increasing tertiles of Lp-PLA2 activity were 1.17 (0.76-1.80) and 1.21 (0.79-1.88) compared with the first tertile (P for trend ¼ 0.65). The model including all confounding factors without sPLA2 showed an ROC-AUC of 0.809. Adding sPLA2 activity to that model increased the C-statistics to 0.813 (P ¼ 0.24). An analysis using the likelihood ratio test showed that adding sPLA2 activity to the model including all confounding variables resulted in a statistically significant improvement in model fit (P ¼ 0.01). Another analysis of discrimination using IDI showed an improvement by 0.005, although not significant (SE ¼ 0.00313, P ¼ 0.10931).
sPLA2 activity was also independently related to all-cause mortality (n ¼ 110) after multivariable adjustment. The hazard risks of death with increasing tertiles of sPLA2 activity were 1.81 (0.97-3.38) and 2.28 (1.28-4.05) compared with the first tertile (P for trend ¼ 0.019). The corresponding hazard risks for recurrent MI (n ¼ 35) were 1.03 (0.43-2.47) and 0.99 (0.40-2.40) compared with the first tertile (P for trend ¼ 0.99). When sPLA2 and Lp-PLA2 activities were considered as continuous variables, sPLA2 (fully adjusted HR 1.19 for 1 SD increase, 95% CI: 1.02-1.39, P ¼ 0.03), but not Lp-PLA2 (HR 1.02, 95% CI: 0.85-1.21, P ¼ 0.85), activity predicted death or recurrent MI during the 1-year follow-up.
After 2 years of follow-up, the hazard ratios for death or recurrent MI (n ¼ 181) were 1.57 (95% CI: 1.02 -2.44) and 3.01 (2.03 -4.45) in the second and third tertiles of sPLA2 activity, respectively, compared with the lowest tertile (P for trend , 0.0001). After adjustment, the hazard risks of death or recurrent MI with increasing 
Discussion
The present study showed that sPLA2 activity was associated with both carotid atherosclerosis and stenosis at MR angiography and predicted all-cause mortality independently of a large set of traditional risk factors in a population-based sample as well as death or MI in a sample of post-MI patients. Lipoprotein-associated phospholipase A2 activity did not show such associations with atherosclerosis nor did it predict mortality in any of the samples. Thus, both in the primary prevention setting and in secondary prevention, sPLA2, but not Lp-PLA2, activity seems to be related to atherosclerosis and future mortality.
Traditional risk factors
Of the traditional risk factors included in the Framingham risk score, sPLA2 activity was only related to gender and age, whereas Lp-PLA2 activity was fairly strongly related to LDL-C. This finding was not surprising since Lp-PLA2 is bound to LDL-C. Of the other emerging risk factors evaluated sPLA2 activity was related to CRP and a reduced kidney function, emphasizing the known role of sPLA2 in inflammation.
Atherosclerosis
In the present study, atherosclerosis was evaluated in two different ways. First, using carotid artery ultrasound by which the number of carotid arteries affected by plaques was recorded. Second, by whole-body magnetic resonance angiography (WBMRA), we calculated an atherosclerotic score summarizing the stenotic burden in the larger arteries. It has previously been shown that the risk of future CV events increases by the number of affected carotid arteries, 17 and we have shown the atherosclerotic score at WBMRA to be associated with coronary risk. 18 In the present setting, sPLA2, but not Lp-PLA2, activity was related to the degree of atherosclerosis as evaluated by both of these imaging modalities. This association was seen independently of multiple risk factors, and in fact the point estimates for these relationships become stronger following adjustment emphasizing the independent role of sPLA2 activity in this respect.
Lp-PLA2 and all sPLA2 isoforms have been shown previously to be expressed in human atherosclerotic plaques and to be associated with signs of plaque instability. 1,3 -7 However, since sPLA2, but not Lp-PLA2, activity is significantly associated with the inflammatory response, our findings lend further support to the role of immuno-inflammatory pathways in the development of atherosclerosis in humans.
Clinical events in primary and secondary prevention settings sPLA2 activity was an independent predictor of all-cause mortality in the randomly selected elderly population during a median follow-up of 7 years. Likewise, sPLA2 activity was an independent predictor of future death or MI in post-MI patients. In both samples, subjects with the highest levels of sPLA2 activity had approximately a doubled risk of reaching the end-point compared with those with low levels even following adjustment for multiple risk factors.
It has previously been shown that sPLA2 activity was a predictor of CV events both in CV patient samples and in a population study. 19, 20 The present study is the first to show its predictive power regarding all-cause mortality and to extend the findings to an aged population.
Lp-PLA2 activity was not associated with atherosclerosis or clinical events. This is in accordance with a recent published meta-analysis on the predictive power of Lp-PLA2; the activity of this enzyme was not predictive of future CV or non-CV mortality in patients with no history of coronary heart disease and was not predictive of recurrent events in patients with acute ischaemic disease. 21 A power analysis in the present PIVUS sample showed that the study had a 80% power to detect a HR of 1.17 for an independent variable on the SD scale in the Cox hazard analysis. The 95% CI for Lp-LPA2 activity was 0.78-1.13, suggesting that the point estimate for Lp-LPA2 activity was truly below that limit. However, a direct comparison between the two PLA2 activities regarding the predictive power for future mortality in the PIVUS study did not reveal a significant difference (P ¼ 0.076). Thus, it cannot be claimed in the present study that sPLA2 activity is a better predictor than Lp-PLA2 activity.
Limitations of the study
The PIVUS sample is limited to Caucasians aged 70, whereas in FAST-MI, more than 99% of patients were Caucasians. 16 So, caution should be made to draw conclusions to other ethnic and age groups. The fact that all participants were aged 70 in the PIVUS study might explain the modest C-statistic AUC for the major risk factors.
The present population-based sample had a moderate participation rate. However, an analysis of non-participants showed the Circulating levels of sPLA2 and Lp-PLA2 activities present sample to be fairly representative of the total population regarding most CV disorders and drug intake.
We do not have data on cause of death in PIVUS and it will take another 2-3 years to receive those data from the official Swedish registers. Thus, for the time being, we cannot evaluate CV mortality. Part of the relationship between sPLA2 activity and all-cause mortality in PIVUS might be due to the role of sPLA2 in cancer. 22 It could, however, be shown that the HR for sPLA2 activity regarding all-cause mortality was reduced (but still significant) when adjusted for the presence of carotid plaques, suggesting a mechanistic link whereby high levels of sPLA2 activity could predict future mortality.
The associations between sPLA2 activity, Lp-PLA2 activity, and the indices of atherosclerosis were based on a cross-sectional analysis and therefore have to be reproduced in prospective studies before any firm conclusions could be drawn.
Only circulating levels of sPLA2 and Lp-PLA2 activities were measured. Blood levels of Lp-PLA2 activity may not constitute a good indicator of enzyme activity within atherosclerotic lesions. Another limitation is that only one measurement of the activities of the PLA2s were performed, precluding for taking regression dilution bias into account.
Finally, only the activity, not the mass, of the enzymes was measured. However, no advantage of measuring mass compared with activity have been shown in previous studies. 19, 20, 23, 24 In addition, the current therapeutic strategies targeting these phospholipases in CV disease involve the use of inhibitors of enzyme activity. 25, 26 Interestingly, selective sPLA2 or Lp-PLA2 inhibitors are currently being tested in phase III clinical trials in patients with coronary artery disease. 27 Although our present data do not prove causality of associations, they suggest that sPLA2 inhibitors may hold promise in reducing hard events after an index acute MI.
Conclusion
sPLA2 activity, but not Lp-PLA2, activity was related to atherosclerosis and increased risk of all-cause mortality in a sample of elderly subjects and predicted mortality or recurrent MI in a sample of post-MI patients.
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